Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bicycle Therapeutics Ltd (BCYC)
NASDAQ:BCYC
Holding BCYC?
Track your performance easily
BCYC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.54 - $28.20
Previous Close$24.41
Volume26.34K
Average Volume (3M)276.64K
Market Cap
$1.70B
Enterprise Value$1.20B
Total Cash (Recent Filing)$526.40M
Total Debt (Recent Filing)$40.08M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Oct 31, 2024EPS Estimate
-$0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.81
Shares Outstanding68,993,458
10 Day Avg. Volume519,665
30 Day Avg. Volume276,642
Standard Deviation0.19
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.93
Price to Sales (P/S)43.53
Price to Cash Flow (P/CF)-10.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue44.36
Enterprise Value/Gross Profit44.36
Enterprise Value/Ebitda-7.06
Forecast
1Y Price Target
$38.25Price Target Upside55.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Bicycle Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical DataZelenectide pevedotin demonstrates competitive efficacy and a favorable safety profile in metastatic urothelial cancer patients.
Financial PositionMultiple partnerships providing non-dilutive capital and a strong cash position of $961.4 million support Bicycle's unique investment opportunity.
Pipeline ProgressIncremental positive pipeline updates at ESMO highlight promising advancements for Bicycle's cancer treatments.
Bears Say
Clinical TrialsThe Duravelo-2 study has 11 active sites, well below the target enrollment of 200 sites, raising concerns about whether BCYC can efficiently reach its enrollment targets.
Market CompetitionPadcev, the current nectin-4 market leader, has significantly penetrated the market, making it challenging for BT-8009 to displace it as the standard of care.
Stock DowngradeDowngrading BCYC stock from Buy to Neutral ahead of the company's ESMO updates, as no significant share price movement is anticipated.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BCYC FAQ
What was Bicycle Therapeutics Ltd’s price range in the past 12 months?
Bicycle Therapeutics Ltd lowest stock price was $12.54 and its highest was $28.20 in the past 12 months.
What is Bicycle Therapeutics Ltd’s market cap?
Currently, no data Available
When is Bicycle Therapeutics Ltd’s upcoming earnings report date?
Bicycle Therapeutics Ltd’s upcoming earnings report date is Oct 31, 2024 which is in 42 days.
How were Bicycle Therapeutics Ltd’s earnings last quarter?
Bicycle Therapeutics Ltd released its earnings results on Aug 06, 2024. The company reported -$0.77 earnings per share for the quarter, beating the consensus estimate of -$1.108 by $0.338.
Is Bicycle Therapeutics Ltd overvalued?
According to Wall Street analysts Bicycle Therapeutics Ltd’s price is currently Undervalued.
Does Bicycle Therapeutics Ltd pay dividends?
Bicycle Therapeutics Ltd does not currently pay dividends.
What is Bicycle Therapeutics Ltd’s EPS estimate?
Bicycle Therapeutics Ltd’s EPS estimate is -$0.8.
How many shares outstanding does Bicycle Therapeutics Ltd have?
Bicycle Therapeutics Ltd has 47,501,358 shares outstanding.
What happened to Bicycle Therapeutics Ltd’s price movement after its last earnings report?
Bicycle Therapeutics Ltd reported an EPS of -$0.77 in its last earnings report, beating expectations of -$1.108. Following the earnings report the stock price went up 7.354%.
Which hedge fund is a major shareholder of Bicycle Therapeutics Ltd?
Among the largest hedge funds holding Bicycle Therapeutics Ltd’s share is Baker Bros Advisors LP. It holds Bicycle Therapeutics Ltd’s shares valued at 190M.
---
Bicycle Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.25 (55.36% Upside)
$38.25 (55.36% Upside)
Blogger Sentiment
Bullish
BCYC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 8.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $142.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.3%
Last 30 Days ▲ 11.3%
Last 30 Days ▲ 11.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.13%
12-Months-Change
Fundamentals
Return on Equity
-30.27%
Trailing 12-Months
Asset Growth
132.81%
Trailing 12-Months
Company Description
Bicycle Therapeutics Ltd
Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
---
BCYC Stock 12 Month Forecast
Average Price Target
$38.25
▲(55.36% Upside)
Technical Analysis
Mersana Therapeutics
―
Fate Therapeutics
―
Blueprint Medicines
―
Immunocore Holdings
―
Best Analysts Covering BCYC
1 Year
1 Year Success Rate
13/19 ratings generated profit
1 Year Average Return
+36.82%
reiterated a buy rating 3 days ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 68.42% of your transactions generating a profit, with an average return of +36.82% per trade.
---